Laser vs vaginal conjugated estrogen in postmenopausal women

Evaluation of efficacy and safety of fractional co2 vs vaginal conjugated estrogen in postmenopausal women diagnosed as having vulvovaginal atrophy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017050433817N1

Enrollment

130

Registered

2017-06-08

Start date

2017-05-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vulvovaginal atrophy. Postmenopausal atrophic vaginitis

Interventions

Intervention 1: The Fractional CO2 laser with Angela trademark( Fractional CO2 LASER MX-7000 smart pulse) , the treatment will be used for 3 Sessions and 4 weeks intervals. Intervention 2: topical con

n = 30) administered once daily for two weeks, then twice weekly for 8 weeks.

Treatment - Other

Treatment - Drugs

The Fractional CO2 laser with Angela trademark( Fractional CO2 LASER MX-7000 smart pulse) , the treatment will be used for 3 Sessions and 4 weeks intervals

topical conjugated estrogen (0.625 mg conjugated equine estrogens per 1 g vaginal cream

Eligibility

Sex/Gender

Female

Age

45 Years to 65 Years

Inclusion criteria

Inclusion criteria: (inclusion criteria: women's between 45-65 age suffering from Amenorrhea since 24 months; women's who diagnosed vaginally atrophy in clinical examination; women's who have sexual contract) (exclusion criteria: women who treated with systemic estrogen since 6 months ago; history of cancer; pathologic change in the cervical Pap smear; Renal or liver failure; women taking estrogen therapy in past history; Radiation therapy of the vagina; vulvovaginitis; History of psychotropic drug or opium use)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Vulvovaginal atrophy symptoms. Timepoint: at base line (day 0), 12 weeks post treatment. Method of measurement: visual analog scale measurement.	—

Secondary

Measure	Time frame
Adverse events. Timepoint: at baseline ( day 0), 12 weeks post treatment. Method of measurement: according to patient history.;Female Sexual Function Index. Timepoint: at baseline ( day 0), 12 weeks post treatment. Method of measurement: according to Female Sexual Function Index.;Sexual satisfaction. Timepoint: at baseline ( day 0), 12 weeks post treatment. Method of measurement: visual analog scale measurement.	—

Measure

Time frame

Adverse events. Timepoint: at baseline ( day 0), 12 weeks post treatment. Method of measurement: according to patient history.;Female Sexual Function Index. Timepoint: at baseline ( day 0), 12 weeks post treatment. Method of measurement: according to Female Sexual Function Index.;Sexual satisfaction. Timepoint: at baseline ( day 0), 12 weeks post treatment. Method of measurement: visual analog scale measurement.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHajatzadeh Saadat

Ahvaz Jundishapur University of Medical Sciences

info@ajums.ac.ir+98 61 3161

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026